Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 12, 2018* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
Sep 5, 2018Industry executive adds considerable financial expertise as audit committee chairperson
-
Sep 4, 2018
-
Sep 3, 2018- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder
-
Jul 31, 2018- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention
-
Jul 30, 2018Nearly 70 million doses to be manufactured this season
Jul 2, 2018- Company invests €66 million in Chengdu, Sichuan province, China-
Jun 25, 2018- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin
-
Jun 4, 2018-- Patients treated with cemiplimab experienced robust anti-tumor effects
-
May 21, 2018* In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo.
-
May 16, 2018* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
May 1, 2018-- Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation
-
Apr 25, 2018- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.
Mar 27, 2018* Max SoloStar holds more insulin than any other long-acting insulin pen-
Mar 27, 2018- Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts
-
Mar 10, 2018* Precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins
-
Mar 10, 2018* ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) Injection to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone
